Repligen Corporation (RGEN)

Market Cap	7.42B
Revenue (ttm)	633.51M
Net Income (ttm)	-8.10M
Shares Out	56.03M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	79.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,431
Open	129.58
Previous Close	128.49
Day's Range	128.91 - 133.07
52-Week Range	113.50 - 211.13
Beta	0.96
Analysts	Buy
Price Target	190.25 (+43.7%)
Earnings Date	Nov 12, 2024

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,783
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN
• Website: https://www.repligen.com

Financial Performance

In 2023, Repligen's revenue was $638.76 million, a decrease of -20.31% compared to the previous year's $801.54 million. Earnings were $41.58 million, a decrease of -77.64%.

Analyst Forecast

According to 11 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $190.25, which is an increase of 43.70% from the latest price.

Price Target

$190.25

(43.70% upside)

Analyst Consensus: Buy